[Expression of c-erbB2 protein and its relation to prognosis in 284 primary breast cancer patients]
- PMID: 16875632
[Expression of c-erbB2 protein and its relation to prognosis in 284 primary breast cancer patients]
Abstract
Objective: To investigate the expression of oncoprotein c-erbB2 in primary breast cancer and to analyze its relation to its prognosis.
Methods: Immunohistochemical staining for c-erbB2 was performed on paraffin-embedded specimens of primary breast cancer from 284 patients, and the relation to its prognosis was statistically analyzed.
Results: Positive expression rate of c-erbB2 was 26.8% (76/284) in 284 primary breast cancer patients. Expression of c-erbB2 was positively correlated with the status of lymph node metastasis (P = 0.003). Univariate analysis indicated that c-erbB2 expression is a significant prognostic factor for the disease-free survival (DFS) (P = 0.024) and overall survival (OS) (P = 0.002), while multivariate analysis demonstrated that c-erbB2 is an independent prognostic factor for OS (P = 0.023). Moreover, tumors with c-erbB2 positive expression are more tend to metastasis to other viscera than those with c-erbB2 negative. c-erbB2 expression has different prognostic values for patients with different status of estrogen receptor (ER) and lymph node metastasis.
Conclusion: c-erbB2 expression is an independent prognostic factor for total survival time in primary breast cancer patients, and its prognostic values are different according to the different ER status and lymph node metastasis.
Similar articles
-
Prognostic value of c-erbB2 expression in breast cancer.J Surg Oncol. 2002 Apr;79(4):216-23. doi: 10.1002/jso.10079. J Surg Oncol. 2002. PMID: 11920778
-
[Clinical characteristics and prognosis of breast cancer patients with vascular invasion].Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):137-40. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17645853 Chinese.
-
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.BMC Cancer. 2007 Apr 12;7:63. doi: 10.1186/1471-2407-7-63. BMC Cancer. 2007. PMID: 17430582 Free PMC article.
-
259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687650 Review.
-
Pathologic prognostic factors for patients with breast carcinoma. Which factors are important.Surg Oncol Clin N Am. 1997 Jul;6(3):415-62. Surg Oncol Clin N Am. 1997. PMID: 9210351 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous